FindTrial
Sign In

RMC-9805

DRUG6 trials

Sponsors

Revolution Medicines Inc., Revolution Medicines, Inc., Tango Therapeutics, Inc.

Conditions

Advanced Solid TumorsCRCColorectal CancerColorectal Cancer (CRC)Gastrointestinal CancerKRAS G12C-mutated Solid Tumors, Lung CancerKRAS, NRAS, HRAS-mutated NSCLCLung Cancer

Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingNCT06040541
Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), Non-small Cell Lung Cancer (NSCLC) +1
Start: 2023-09-07End: 2027-04-30Target: 604Updated: 2025-08-28
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingNCT06162221
Revolution Medicines, Inc.KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer +2
Start: 2024-01-18End: 2028-12-01Target: 616Updated: 2026-03-09
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingNCT06445062
Revolution Medicines, Inc.Colorectal Cancer, CRC, Gastrointestinal Cancer +3
Start: 2024-05-24End: 2027-07-15Target: 1130Updated: 2026-04-01
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RecruitingNCT06922591
Tango Therapeutics, Inc.Lung Cancer, MTAP Deletion, NSCLC +5
Start: 2025-05-31End: 2027-12-31Target: 183Updated: 2025-12-11

Phase 2

A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
RecruitingCTIS2025-521681-10-00
Revolution Medicines Inc.Lung Cancer
Start: 2025-10-02Target: 84Updated: 2025-12-11
A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
RecruitingCTIS2025-521147-21-00
Revolution Medicines Inc.Lung Cancer
Start: 2025-10-08Target: 130Updated: 2026-01-14

Related Papers

Abstract A118: Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC
Cancer Research2025-09-28
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors
Science2025-07-2414 citations
Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors
Cancer Research2025-05-224 citations
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
Journal of Medicinal Chemistry2025-03-0832 citations
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
Journal of Medicinal Chemistry2025-02-2422 citations
Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.
Journal of Clinical Oncology2025-01-2712 citations
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Cancer Discovery2024-04-09213 citations
Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor
Cancer Research2024-04-0514 citations